BioVie to Present Protocol Design for Upcoming Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at 2024 ATMRD Congress
BIVIBioVie(BIVI) GlobeNewswire News Room·2024-06-20 20:00

CARSON CITY, Nev., June 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced two poster presentations at the Advanced Therapeutics in Movement and Related Disorders Congress® (ATMRD Congress) being held June 21-25, 2024 in Washington, D.C. The presentation Assessment of Bezisterim (NE3107) in Patients with ...